Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Net Issuance of Common Stock
Adaptimmune Therapeutics PLC
Net Issuance of Common Stock Peer Comparison
Competitive Net Issuance of Common Stock Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Net Issuance of Common Stock
$29.9m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Net Issuance of Common Stock
$21.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Net Issuance of Common Stock
$27k
|
CAGR 3-Years
-93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Net Issuance of Common Stock
$249.2m
|
CAGR 3-Years
32%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Net Issuance of Common Stock
£34.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
221%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Adaptimmune Therapeutics PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
29.9m
USD
Based on the financial report for Mar 31, 2024, Adaptimmune Therapeutics PLC's Net Issuance of Common Stock amounts to 29.9m USD.
What is Adaptimmune Therapeutics PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-22%
Over the last year, the Net Issuance of Common Stock growth was 130%. The average annual Net Issuance of Common Stock growth rates for Adaptimmune Therapeutics PLC have been -51% over the past three years , -22% over the past five years .